120 related articles for article (PubMed ID: 22002075)
21. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
[TBL] [Abstract][Full Text] [Related]
23. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
[TBL] [Abstract][Full Text] [Related]
24. Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH.
Mandosi E; Fallarino M; Rossetti M; Gatti A; Morano S
Diabetes Res Clin Pract; 2009 May; 84(2):e18-20. PubMed ID: 19297054
[TBL] [Abstract][Full Text] [Related]
25. Insulin detemir: a long-acting insulin product.
Jones MC; Patel M
Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
[TBL] [Abstract][Full Text] [Related]
26. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups.
Hompesch M; Troupin B; Heise T; Elbroend B; Endahl L; Haahr H; Heinemann L
Diabetes Obes Metab; 2006 Sep; 8(5):568-73. PubMed ID: 16918592
[TBL] [Abstract][Full Text] [Related]
27. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
28. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
Tripathi S; Chandalia HB; Rao PV; Badgandi M; Patni R; Subbanna PK; Shetty R; Kumar H
J Indian Med Assoc; 2011 Apr; 109(4):275-8. PubMed ID: 22187803
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
[TBL] [Abstract][Full Text] [Related]
30. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
31. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
32. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
Danne T; Lüpke K; Walte K; Von Schuetz W; Gall MA
Diabetes Care; 2003 Nov; 26(11):3087-92. PubMed ID: 14578244
[TBL] [Abstract][Full Text] [Related]
33. [Insulin detemir compared with NPH insulin. No significant differences identified in the studies].
Liedholm H; Linné AB
Lakartidningen; 2006 May 3-9; 103(18):1417, 1419-22, 1424-6. PubMed ID: 16729454
[No Abstract] [Full Text] [Related]
34. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
Lin JC; Shau WY; Lai MS
Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
[TBL] [Abstract][Full Text] [Related]
35. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
36. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
[TBL] [Abstract][Full Text] [Related]
37. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
[TBL] [Abstract][Full Text] [Related]
38. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
[TBL] [Abstract][Full Text] [Related]
39. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.
Raslová K; Tamer SC; Clauson P; Karl D
Clin Drug Investig; 2007; 27(4):279-85. PubMed ID: 17358100
[TBL] [Abstract][Full Text] [Related]
40. Insulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin.
Begg DP; May AA; Mul JD; Liu M; D'Alessio DA; Seeley RJ; Woods SC
Diabetes; 2015 Jul; 64(7):2457-66. PubMed ID: 25667307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
